A Study to Learn About mRNA Vaccines Against Influenza in Adults
ConditionHealthy Adults
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorPfizer
About this trial
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus).
This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison.
Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.
Eligibility criteria
Qualifiers
None
Disqualifiers
Tested positive for influenza ≤5 months (150 days) prior to Visit 1 (Day 1).
Vaccination with any investigational or licensed influenza vaccine ≤5 months (150 days) before Visit 1 (Day 1).
Receipt of antiviral therapies for influenza (eg, Tamiflu) ≤5 months (150 days) prior to Visit 1 (Day 1).
Trial design
Treatments tested in this trial
- Vaccine Candidate #1
- Vaccine Candidate #2
- Vaccine Candidate #3
- Vaccine Candidate #4
- Vaccine Candidate #5
- Vaccine Candidate #6
- TIV1 or TIV2
Treatment groups
770 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov